• SENSEX
    NIFTY 50
Market

CNBC-TV18's top stocks to watch out for on August 21

Updated : 2019-08-21 07:56:18

Indian benchmark indices, the S&P BSE Sensex and NSE’s Nifty 50, are likely to open lower on Wednesday, tracking weak global markets, as the absence of any bold reforms by the government to support the economy is likely to weigh on the investor sentiment. In Asia, stocks declined as US President Donald Trump showed no signs of backing down in his trade war with China. At 7:00 AM, the SGX Nifty futures traded lower by 32 points, or 0.29 percent, at 10,996.50, indicating a negative start for the Sensex and the Nifty.

Central Bank of India: The PSU bank is planning to mop up around Rs 3,000 crore in core capital from markets in the next two months. This capital is excluding the fund infusion that is likely to come from the government, Pallav Mohapatra, managing director and chief executive, told reporters on the sidelines of the annual industry conference Fibac. (Image: Company)
Central Bank of India: The PSU bank is planning to mop up around Rs 3,000 crore in core capital from markets in the next two months. This capital is excluding the fund infusion that is likely to come from the government, Pallav Mohapatra, managing director and chief executive, told reporters on the sidelines of the annual industry conference Fibac. (Image: Company)
United Spirits: The recovery official of the Debt Recovery Tribunal sold more than 33 lakh shares of United Spirits for around Rs 196 crore. The BSE block deal data showed that the recovery official sold a total of 33,10,515 shares of United Spirits at a price of Rs 591.95 per share. (Image: Company)
United Spirits: The recovery official of the Debt Recovery Tribunal sold more than 33 lakh shares of United Spirits for around Rs 196 crore. The BSE block deal data showed that the recovery official sold a total of 33,10,515 shares of United Spirits at a price of Rs 591.95 per share. (Image: Company)
Dr Reddy's Labs: The USFDA has issued eight observations to Dr Reddy's Laboratories after the inspection of its Duvvada facility in Andhra Pradesh. The audit of the company's formulations manufacturing plant (Vizag SEZ Plant 1) completed on Tuesday. The FDA Form 483 notifies the company's management of objectionable conditions. In other news, it has launched generic anti-epileptic Vigabatrin powder for oral solution in the US market. (Image: Reuters)
Dr Reddy's Labs: The USFDA has issued eight observations to Dr Reddy's Laboratories after the inspection of its Duvvada facility in Andhra Pradesh. The audit of the company's formulations manufacturing plant (Vizag SEZ Plant 1) completed on Tuesday. The FDA Form 483 notifies the company's management of objectionable conditions. In other news, it has launched generic anti-epileptic Vigabatrin powder for oral solution in the US market. (Image: Reuters)
NMDC: Karnataka government has withdrawn the approval to extend the mining lease period of NMDC at Donimalai and auction the said block. The company has filed revision application against the state with Ministry of Mines and the hearing is fixed on August 21.
NMDC: Karnataka government has withdrawn the approval to extend the mining lease period of NMDC at Donimalai and auction the said block. The company has filed revision application against the state with Ministry of Mines and the hearing is fixed on August 21.
Sun Pharma Advanced Research Company: US company Abraxis Biosciences LLC filed plea against the company, alleging that company's filing of New Drug Application (NDA) for Taclantis injection is an act of infringement of the Orange Book listed patents for Abraxane. SPARC believes that the lawsuit is without merit and will vigorously defend against these allegations. (Stock Image)
Sun Pharma Advanced Research Company: US company Abraxis Biosciences LLC filed plea against the company, alleging that company's filing of New Drug Application (NDA) for Taclantis injection is an act of infringement of the Orange Book listed patents for Abraxane. SPARC believes that the lawsuit is without merit and will vigorously defend against these allegations. (Stock Image)
Housing Development and Infrastructure Limited: HDIL said it has been admitted under the provisions of the Insolvency Bankruptcy Code (IBC) in National Company Law Tribunal (NCLT). It is noted that Bank of India filed petition under Section 7 of IBC to initiate insolvency proceedings against HDIL. The NCLT on June 4 had warned given HDIL four weeks’ time to pay Rs 98 crore to Bank of India and warned the company that faliure to do so would initiate insolvency proceedings. (Image: Company)
Housing Development and Infrastructure Limited: HDIL said it has been admitted under the provisions of the Insolvency Bankruptcy Code (IBC) in National Company Law Tribunal (NCLT). It is noted that Bank of India filed petition under Section 7 of IBC to initiate insolvency proceedings against HDIL. The NCLT on June 4 had warned given HDIL four weeks’ time to pay Rs 98 crore to Bank of India and warned the company that faliure to do so would initiate insolvency proceedings. (Image: Company)
Jet Airways, IndiGo, SpiceJet: The Civil Aviation Ministry has extended the validity of all Jet Airways slots, which were allocated to other domestic airlines, till December, CNBC-TV18 reported, citing a senior government official. While the slot allocation committee has been working on distributing the vacant slots of Jet Airways to other carriers since March 20. (Image: Reuters)
Jet Airways, IndiGo, SpiceJet: The Civil Aviation Ministry has extended the validity of all Jet Airways slots, which were allocated to other domestic airlines, till December, CNBC-TV18 reported, citing a senior government official. While the slot allocation committee has been working on distributing the vacant slots of Jet Airways to other carriers since March 20. (Image: Reuters)
Alembic Pharmaceuticals: The company's Bioequivalence facility in Vadodara was inspected by the US Food and Drug Administration between August 12 and 15and between August 12 and 20 for a) Bioequivalence Bioanalytical; and b) Bioequivalence Clinical. There were no 483s issued by USFDA at the end of the inspection. (Stock Image)
Alembic Pharmaceuticals: The company's Bioequivalence facility in Vadodara was inspected by the US Food and Drug Administration between August 12 and 15and between August 12 and 20 for a) Bioequivalence Bioanalytical; and b) Bioequivalence Clinical. There were no 483s issued by USFDA at the end of the inspection. (Stock Image)
Deepak Nitrite: Deepak Nitrite: ICRA has upgraded the company's long-term rating from A+ to AA- and revised outlook to positive from stable. (Image: Company)
Deepak Nitrite: Deepak Nitrite: ICRA has upgraded the company's long-term rating from A+ to AA- and revised outlook to positive from stable. (Image: Company)
Live TV

Ask Our Experts CNBC TV18